Network Pharmacology And Case Report Of Fermented Cordyceps Sinensis Powder (Cs-C-Q80) For The Treatment Of Idiopathic Pulmonary Fibrosis

Objective:1.To investigate the active ingredients,action targets,signaling pathways of Fermented Cordyceps sinensis powder（cs-c-q80）to treat idiopathic pulmonary fibrosis by network pharmacology and explore the underlying mechanism.2.To observe the clinical efficacy as well as safety of Fermented Cordyceps sinensis powder（cs-c-q80）in the treatment of idiopathic pulmonary fibrosis through clinical studies,and the effects on patients’condition related indicators.Method:1.Network pharmacology study:the active ingredient screening and target prediction of Cordyceps sinensis were performed using TCMSP,and the targets related to idiopathic pulmonary fibrosis were obtained by genecards database,OMIM database,drugbank database searching,using Cytoscape v3.8.0 software to construct the visualization network of active ingredients of Cordyceps sinensis idiopathic pulmonary fibrosis related targets,import common targets into STRING database to build common target PPI network.Finally,use DAVID platform for GO and KEGG enrichment analysis,and molecular docking validation of the main active components and key targets was performed using Auto Dock software.2.Clinical case observation:60 patients who met the standard were randomly divided into experimental group and control group,with 30 cases in each group.Both groups were treated with basic symptomatic treatment.The experimental group was treated with Bailing Capsule on the basis of symptomatic treatment.The results were statistically analyzed after 3 months.Result:1.In the Network pharmacology section,thirty eight active ingredients of Cordyceps sinensis were retrieved by network pharmacology method,and seven active ingredients were obtained after screening using OB≥30%and DL≥0.18,corresponding to 203 potential target proteins of active ingredients of Cordyceps sinensis.When the active ingredient targets of Cordyceps sinensis were intersected with the disease targets associated with idiopathic pulmonary fibrosis,84 core acting target proteins were obtained,corresponding to four active ingredients,and through the analysis of the PPI network of the common targets,the potential targets were JUN,CCND1,PPARG,ESR1,MARK14,and so on.The main signaling pathways obtained from KEGG enrichment analysis were TNF,VEGF,p53,c AMP,MARK,and so on.Molecular docking results indicated that active ingredients could form stable complexes with target proteins.2.In the clinical case observation section,statistical analysis of the results revealed that after3 months of treatment,there was a significant difference between the experimental and control groups in terms of the medical syndrome score（P<0.01）,the SGRQ score（P<0.05）,and the treatment effect in the experimental group was superior to that in the control group.There were no significant differences in lung function,6MWT,Sp O₂,and m MRC scores between the two groups（P>0.05）.There were no significant abnormalities in the safety indicators before and after treatment in the two groups,and no serious adverse reactions occurred.Conclusions:1.The results of network pharmacology show that the mechanism of Fermented Cordyceps sinensis powder（cs-c-q80）in the treatment of idiopathic pulmonary fibrosis involves multiple components,multiple action targets and multiple signal pathways.It can play a therapeutic role by inhibiting apoptosis,reducing inflammatory response and improving antioxidant capacity,which provides a theoretical basis for clinical research.2.Clinical case observation indicated that Fermented Cordyceps sinensis powder（cs-c-q80）could effectively improve the TCM syndrome and quality of life in patients with idiopathic pulmonary fibrosis,with some clinical efficacy and safety.